-
1 Comment
Bioxyne Limited is currently in a long term uptrend where the price is trading 92.3% above its 200 day moving average.
From a valuation standpoint, the stock is 98.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.7.
Bioxyne Limited's total revenue sank by 10.4% to $1M since the same quarter in the previous year.
Its net income has dropped by 121.3% to $-432K since the same quarter in the previous year.
Finally, its free cash flow fell by 27.4% to $77K since the same quarter in the previous year.
Based on the above factors, Bioxyne Limited gets an overall score of 2/5.
| Exchange | AU |
|---|---|
| CurrencyCode | AUD |
| ISIN | AU000000BXN6 |
| Sector | Consumer Defensive |
| Industry | Packaged Foods |
| Market Cap | 90M |
|---|---|
| PE Ratio | 17.54 |
| Target Price | None |
| Beta | 0.54 |
| Dividend Yield | None |
Bioxyne Limited, together with its subsidiaries, manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czechia, Switzerland, France, Germany, and Japan. It operates through Pharmaceutical Manufacture and Wholesale Supply of Novel Medicines, Cannabis, Psilocybin, and MDMA; Manufacture and Distribution (Wholesale, Online, and Retail) of Consumer Health and Novel Food Products; and Wholesale of Patented Probiotics segments. The company offers active pharmaceutical ingredients and starting materials; plant-based food products, such as non-controlled cannabis extracts and cannabidiol; food grade mushroom extracts/psilocybin; medicinal and prescription cannabis products, including pastilles, vape, oral mucosal oils, flower, and suppositories; SL-NAD+ wafers; MDMA; white label manufactured wellness products; health and wellness supplements; and nootropic and skincare products. It also provides Lactobacillus fermentum VRI-003 PCC, a probiotic formulation for gastrointestinal health and immunity; Progastrim for gut and immune health; and proTract for atopic dermatitis. In addition, the company is involved in the contract manufacturing of final dose form products, including capsules, tablets, inhalables, oral solutions, and herbal preparations; import, export, manufacture, and supply of controlled drugs and medicinal products; research and development of formulations, products, and processes related to health, wellness, and medicine; and provision of telemedicine services. Further, it operates CanXChange, a machine-learning powered B2B wholesale and custody technology platform. The company offers its products to cultivators, manufacturers, pharmacies, clinics, and patients under the Breathe Life Science, Dr Watson, Mirai Solution, and Apothecary CBD brands. It sells its products through wholesale, retail, and online. Bioxyne Limited is headquartered in Sydney, Australia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BXN.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
